Under behandlingen var serum- HBV- DNA- niveauerne betydeligt lavere end ved baseline i op til 48 uger af behandlingen, mens ALAT- niveauerne faldt progressivt fra uge 12.
During therapy, serum HBV DNA levels were significantly lower compared to baseline for up to 48 weeks of treatment while ALT levels declined progressively from week 12.